Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.35 |
| ▸ | HTR2C | P28335 | 10/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19127058 | 0.90 | SIGMAR1 (0.38) | PGR | |
| SCHEMBL771123 | 0.89 | HTR2A (0.40) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL19127865 | 0.84 | — | — | |
| SCHEMBL172541 | 0.77 | — | — | |
| SCHEMBL81996 | 0.77 | — | — | |
| SCHEMBL172592 | 0.77 | — | — | |
| SCHEMBL3948389 | 0.76 | HTR2A (0.36) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL22830254 | 0.74 | HTR2A (0.37) | HTR2AHTR2CMCHR1SLC6A2L3MBTL1 | |
| SCHEMBL28166245 | 0.74 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL28166243 | 0.74 | HRH3 (0.38) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | claimed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | claimed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | claimed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | claimed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | HTR2A 208/4885HTR2C 112/4885MCHR1 253/4885 |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | HTR2A 208/4885HTR2C 112/4885MCHR1 253/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HTR2A 4863/4885HTR2C 4660/4885MCHR1 4788/4885 |
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | HTR2A 236/4885HTR2C 138/4885MCHR1 42/4885 |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | HTR2A 208/4885HTR2C 112/4885MCHR1 253/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | HTR2A 208/4885HTR2C 112/4885MCHR1 253/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | HTR2A 4198/4885HTR2C 3231/4885MCHR1 4293/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | HTR2A 208/4885HTR2C 112/4885MCHR1 253/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | HTR2A 2109/4885HTR2C 1421/4885MCHR1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.